AWM
CRBP icon

Accel Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Accel Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-46
Closed -$334 – 307
2023
Q1 		$334 Hold
46
– – ﹤0.01% 1228
2022
Q4 		$153 Hold
46
– – ﹤0.01% 1044
2022
Q3 		$0 Hold
46
– – ﹤0.01% 1063
2022
Q2 		$0 Hold
46
– – ﹤0.01% 1028
2022
Q1 		$1K Hold
46
– – ﹤0.01% 898
2021
Q4 		$1K Hold
46
– – ﹤0.01% 902
2021
Q3 		$1K Hold
46
– – ﹤0.01% 803
2021
Q2 		$3K Hold
46
– – ﹤0.01% 834
2021
Q1 		$3K Hold
46
– – ﹤0.01% 798
2020
Q4 		$2K Buy
+46
New +$1.72K ﹤0.01% 778

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Accel Wealth Management's CRBP Position: Q2 2023 in Review

Accel Wealth Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2023, closing a stake of 46 shares — an estimated $334 sold.

Accel Wealth Management first reported a position in CRBP in Q4 2020 and held it in 10 quarters. The position peaked at $3K in Q2 2021. 28 funds tracked by Wall St. Rank hold CRBP as of Q2 2023.

  • Accel Wealth Management reported no remaining Corbus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Accel Wealth Management sold 46 Corbus Pharmaceuticals shares in Q2 2023, an estimated $334.
  • Accel Wealth Management first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Accel Wealth Management's Corbus Pharmaceuticals position peaked at $3K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.